能否预测炎症对伏立康唑暴露的影响?综述
伏立康唑药代动力学个体间和个体内变异大且呈非线性,推荐通过测定最低血浆浓度进行治疗药物监测。炎症是导致其变异的重要因素,侵袭性真菌感染常伴炎症,可能引起伏立康唑过度暴露。本综述汇总成人炎症对伏立康唑药代动力学影响的现有数据,并评估C反应蛋白的作用、炎症对患者代谢表型的影响及可用于预测炎症效应的工具。
要点
- 伏立康唑药代动力学呈非线性,个体间和个体内变异大,剂量调整困难。
- 推荐通过测定最低血浆浓度进行治疗药物监测。
- 炎症是伏立康唑药代动力学高变异性的因素之一,可能增加过度暴露风险。
核心结论
- 预测炎症对伏立康唑药代动力学的影响有助于优化抗真菌治疗并改善患者管理。
研究设计与样本
- 综述,汇总成人人群中炎症对伏立康唑药代动力学影响的现有数据。
主要发现
- 伏立康唑药代动力学呈非线性,个体间和个体内变异大。
- 导致伏立康唑药代动力学高变异性的因素包括年龄、进食(降低吸收)、肝功能、CYP2C19基因遗传多态性、药物相互作用和炎症。
- 侵袭性真菌感染常与炎症相关,可能带来伏立康唑过度暴露的风险。
关键数值与推荐
- 推荐通过测定最低血浆浓度进行治疗药物监测。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Voriconazole is a triazole antifungal indicated for invasive fungal infections that exhibits a high degree of inter-individual and intra-individual pharmacokinetic variability. Voriconazole pharmacokinetics is non-linear, making dosage adjustments more difficult. Therapeutic drug monitoring is recommended by measurement of minimum plasma concentrations. Several factors are responsible for the high pharmacokinetic variability of voriconazole: age, feeding (which decreases absorption), liver function, genetic polymorphism of the CYP2C19 gene, drug interactions and inflammation. Invasive fungal infections are indeed very frequently associated with inflammation, which engenders a risk of voriconazole overexposure. Many studies have reviewed this topic in both the adult and paediatric populations, but few studies have focused on the specific point of the prediction, to evaluate the influence of inflammation on voriconazole pharmacokinetics. Predicting the impact of inflammation on voriconazole pharmacokinetics could help optimize antifungal therapy and improve patient management. This review summarizes the existing data on the influence of inflammation on voriconazole pharmacokinetics in adult populations. We also evaluate the role of C-reactive protein, the impact of inflammation on patient metabolic phenotypes, and the tools that can be used to predict the effect of inflammation on voriconazole pharmacokinetics.
引用
- Boglione-Kerrien C, Zerrouki S, Le Bot A, et al. Can we predict the influence of inflammation on voriconazole exposure? An overview. J Antimicrob Chemother. 2023. PMID: 37796931. doi:10.1093/jac/dkad293
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。